Back

Which treatment attributes do patients with transthyretin amyloid cardiomyopathy value most?

19 May 2025 (09:00 - 10:20)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy (2) Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mrs Anne Carr

Hagersville (Canada)

5 More presentations in this session

Presentation thumbnail
Using dapagliflozin to reduce NT-proBNP and improve symptom in transthyretin cardiac amyloidosis - a series of n-of-1 trials pilot study
Doctor E. Haakansson (Umea, SE)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics and outcomes in a cohort of patients starting treatment with vericiguat in the US.
Doctor A. Michel (Basel, CH)
Abstract Slides Video
Presentation thumbnail
The care-gap for women living with heart failure
Doctor O. Graham (Craigavon, GB)
Abstract Slides Video
Presentation thumbnail
Intermittent levosimendan therapy and survival outcomes in advanced heart failure: insights from a real-world single-centre study
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Ambulatory blood pressure monitoring reveals true significant hypotension in stable HF patients; Is this an overlooked issue?
Doctor G. Bruno (Limerick, IE)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy (2)

The Event

Event poster

Heart Failure 2025

19 May 2025 09:00 CET
You may be interested in
thumbnail
Congress Session
Transthyretin amyloidosis: long-term outcomes and emerging therapies
thumbnail
Congress Presentation
Outcomes with early access tafamidis in patients with variant transthyretin amyloid cardiomyopathy
thumbnail
Congress Presentation
Clinical presentation and treatment landscape of patients with transthyretin amyloidosis with cardiomyopathy: a real-world study in five European countries and Japan

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources